Publication:


abstract

Recently, 2 monoclonal antibodies that specifically inhibit mitochondrial creatine kinase (MtCK) activity have been developed. In this study, we measured the serum MtCK activity in HIV-1-infected individuals (n = 100) by employing a novel method using these antibodies. The mean serum MtCK activity in 44 patients treated with highly active antiretroviral therapy (HAART) including tenofovir disoproxil fumarate (TDF) was 16.0 IU/L. The MtCK activity was significantly higher in patients receiving TDF than in those receiving HAART without TDF (3.4 IU/L) or in naïve patients (6.9 IU/L) (Tukey-Kramer test, p < 0.0001 and p = 0.0029, respectively). The serum MtCK activity reached a plateau at 1 month after the initiation of TDF administration and decreased upon discontinuation. It showed no significant correlation with the trough plasma TDF concentration, serum creatinine level, or red blood cell count. The activity was elevated in 75% of the patients receiving TDF, and this elevation was specific to TDF; it was not observed with other anti-HIV drugs. In addition, our report emphasizes the careful interpretation of creatine kinase-MB (CK-MB) test results in patients receiving TDF because MtCK in serum could cause false-positive results on a conventional CK-MB test, which does not include MtCK-specific inhibitory antibodies.

Related Articles
Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies.
Scand J Clin Lab Invest. 2009
Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies.
Hoshino T, Sakai Y, Yamashita K, Shirahase Y, Sakaguchi K, Asaeda A, Kishi K, Schlattner U, Wallimann T, Yanai M, et al. Scand J Clin Lab Invest. 2009; 69(6):687-95.
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Antivir Ther. 2006
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Schmid H, Mühlbayer D, Röling J, Sternfeld T, Jülg B, Schlattner U, Nelson PJ, Bogner JR, Wallimann T, Goebel FD. Antivir Ther. 2006; 11(8):1071-80.
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
HIV Med. 2006
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S. HIV Med. 2006 Mar; 7(2):105-11.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Drugs. 2003
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.
Review Variations of muscle mitochondrial creatine kinase activity in mitochondrial diseases.
Biochim Biophys Acta. 1996
Review Variations of muscle mitochondrial creatine kinase activity in mitochondrial diseases.
Bouzidi MF, Enjolras N, Carrier H, Vial C, Lopez-Mediavilla C, Burt-Pichat B, Couthon F, Godinot C. Biochim Biophys Acta. 1996 Jun 7; 1316(2):61-70.